T4	total-participants 565 569	3864
T5	eligibility 570 634	healthy, postmenopausal women at increased risk of breast cancer
T6	control 702 709	placebo
T7	total-participants 711 715	1410
T8	outcome-Measure 1413 1518	effect of risedronate versus placebo for osteopenic women in stratum II randomly allocated to anastrozole
T11	total-participants 1868 1871	150
T13	intervention-participants 2075 2077	77
T14	control-participants 2183 2185	73
T17	outcome 2756 2775	at the lumbar spine
T18	outcome 2837 2846	total hip
T19	intervention-participants 2987 2989	46
T21	outcome 3069 3081	at the spine
T22	outcome 3182 3191	total hip
T24	cv-bin-abs 3458 3460	94
T25	iv-bin-abs 3473 3476	114
T26	outcome 3447 3456	stratum I
T27	outcome 3490 3500	stratum II
T28	cv-bin-abs 3502 3504	39
T29	iv-bin-abs 3522 3524	25
T30	iv-bin-abs 3546 3548	34
T31	iv-bin-abs 3574 3576	34
T32	outcome 3602 3613	stratum III
T33	iv-bin-abs 3615 3617	21
T34	iv-bin-abs 3639 3641	17
T35	outcome 3698 3709	hot flushes
T36	outcome 3711 3719	alopecia
T37	outcome 3721 3735	abdominal pain
T38	outcome 3741 3750	back pain
T23	iv-cont-mean 2122 2126	1·1%
T39	cv-cont-mean 2154 2159	-2·6%
T40	iv-cont-mean 2324 2329	-0·7%
T41	cv-cont-mean 2351 2356	-3·5%
T42	iv-cont-mean 2777 2782	-4·0%
T43	cv-cont-mean 2801 2806	-1·2%
T44	iv-cont-mean 2848 2853	-4·0%
T45	cv-cont-mean 2872 2877	-1·8%
T46	iv-cont-mean 3050 3054	1·2%
T47	cv-cont-mean 3098 3102	3·9%
T48	iv-cont-mean 3201 3205	0·3%
T49	cv-cont-mean 3287 3291	1·5%
T1	intervention 77 104	anastrozole and risedronate
T2	outcome 2044 2066	3 year mean BMD change
T3	outcome 2253 2275	3 year mean BMD change
T9	outcome 3034 3046	BMD increase
T10	outcome-Measure 1559 1598	effect of anastrozole (1 mg/day) on BMD
